BioPorto

Transforming Care Through Actionable Kidney Biomarkers

Business Strategy Update & Pre-announced Q3 2025 Financials

November 6, 2025

Forward-looking statements

References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the “Company” or “BioPorto”), and any further information that may be made available in connection with the subject matter contained herein. By viewing or receiving or reading this presentation or attending any meeting where this presentation is made, you agree to be bound by the limitations, qualifications and restrictions set out below.

This presentation contains forward-looking statements. Words such as “believe”, “expect”, “may”, “plan”, “strategy”, “estimate”, “target” and similar expressions identify such forward-looking statements. Statements other than historical facts included in this presentation concerning our plans, objectives, goals, future events and performance are forward-looking statements. They involve risks, uncertainties and other factors, which may cause actual results, performance and achievements to differ materially from the results discussed in the forward-looking statements. These include numerous assumptions, risks and uncertainties, many of which are beyond BioPorto’s control. These risks and uncertainties are described from time to time in BioPorto’s Announcements and in its 2024 Annual Report under Risk Factors. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date of this presentation.

This presentation is for information purposes only and does not constitute an offer to sell or a solicitation of any offer to buy any securities issued by the Company in any jurisdiction. The information contained herein is not for distribution in the United States of America. This document does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. The Company’s securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold within the United States absent registration or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to offer or solicit an offer to buy any securities in the Company in the United States or to make a public offering of the securities in the United States. Company securities may be sold only to qualified institutional buyers (as defined in Rule 144A under the Securities Act) in reliance on Rule 144A.

The ”Forward” Strategic Plan

*Focus on Execution of **Market Access** & **Commercialization** to transform kidney care*

1 **Adaption**

2 **High Growth**

3 **Expand**



Aspirations

2H 2027 Cash flow Positive

FY 2028 Revenue 150-200m DKK

FY 2028 EBITDA% +15%

Market Access

Strengthen & accelerate execution

Adult Indication	Standard of Care	Instrument Expansion
✓ Adult Clinical Study Ongoing ✓ Expect to obtain FDA clearance in 2027 ✓ Expect to obtain IVDR certification in 2027	✓ Guideline organizations to include biomarkers ✓ Prepare market education for updated guideline(s)	✓ Instrument expansion ✓ Enter further distribution partnerships ✓ Adult indication

Commercialization

Execute diligently the pediatric focus & adult entry preparation in targets markets

US



EU



Process & Messaging

- AKI champions
- Clinical Education
- Lab Validation
- Clinical Operation

- Health Economy
- Operational Support
- Account management

Highlights for the third quarter of 2025

- ✓ A major milestone in the third quarter of 2025 was the delivery of **the first purchase order for ProNephro™ AKI (NGAL) for the US market**, marking the first step in the commercial launch
- ✓ End October, the **enrollment in the Cut-Off study** for ProNephro AKI (NGAL) for US adult use was **completed**
- ✓ The **data collection process** is ongoing but is taking longer time than initial projected. In addition, we have decided to do a **pre-submission to the FDA in Q1 2026**. Consequently, final submission has been postponed to H1 2027

TOTAL REVENUE (Q3 2025)

DKK 10.4 million

7% increase compared to Q3 2024 (10% at constant exchange rates)

ADJUSTED EBITDA (Q3 2025)

DKK (16.8) million

14% decrease compared to Q3 2024

CASH POSITION (END Q3 2025)

DKK 27.6 million

Continued NGAL growth in Q3 2025 vs Q3 2024

Revenue Q3 2025 vs Q3 2024, DKKm



US NGAL RUO	+20% (+27%)
ROW NGAL	-87%
ProNephro AKI™ (NGAL)	+2.1m

Revenue per quarter, DKKm



9M 2025 vs 9M 2024

Total revenue

DKK 28.7m +1% (+2%)

Total NGAL revenue

DKK 19.3m +5% (+7%)

US NGAL +21% (+23%)
ROW NGAL -49%

() Growth at Constant Exchange Rates

NGAL Sales US continuing strong growth projection

US NGAL RUO sales (accumulated 12 months rolling at constant exchange rates)



Revised Financial Guidance 2025

Total revenue in 2025

DKK 40-45m
(Previously DKK 45-50m)

Adjusted EBITDA loss in 2025

DKK 75-80m
(Unchanged)

Sustainable and Attractive Financials towards 2028

High revenue growth and EBITDA positive



- NGAL US growth **2021-2024 with a CAGR of 18%**
- NGAL with **significant growth potential towards 2028** as market matures and # of instruments approved increases
- **Adjusted EBITDA** expected to **turn positive within the next few years**.

Funding

FUNDING NEEDS

- DKK 60 – 70 million is required until cash flow positive in second half of 2027

FUNDING TO MAINTAIN MOMENTUM

- Finalize adult clinical trials to seek FDA clearance for ProNephro AKI™ NGAL
- Maintain and further build up the commercial platform

EXPLORING FUNDING OPTIONS

- Multiple funding options pursued, including share issuance, loan facilities and spin-off of antibody business

Invest in AKI Diagnostic - Invest in BioPorto

- Early detection of AKI (Acute Kidney Injury) represents a **major unmet need**[1]
- BioPorto's ProNephro AKI™ (NGAL) is **the first FDA-cleared test for pediatric AKI assessment**
- Defined pathway for **FDA approval** and **commercial launch** of ProNephro AKI (NGAL) for **adults in US** to **open addressable market**
- **Significant market potential** – Total targeted ICU (Intensive Care Unit) Market estimated at app. USD 700m[2]
- **Growth Case** based on an asset light business model with high margins and clear value drivers towards 2028

1. NephroCheck at 10: addressing unmet needs in AKI diagnosis and risk stratification | Clinical Kidney Journal | Oxford Academic 2. Source: Management estimates | S2N Data, BIS data | US Ped Risk Strat indication is for 3 months through 21yoa